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ABSTRACT  
Scope: Presenting symptoms, distributions and patterns of diseases and vulnerability to 
invasive aspergillosis (IA) are similar between children and adults. However, differences 
exist in the epidemiology and underlying conditions, the usefulness of newer diagnostic 
tools, the pharmacology of antifungal agents and in the evidence from interventional phase 
III clinical trials. Therefore, the European Society for Clinical Microbiology and Infectious 
Diseases (ESCMID) and the European Confederation of Medical Mycology (ECMM) have 
developed a paediatric specific guideline for the diagnosis and management of IA in 
neonates and children.  
Methods: Review and discussion of the scientific literature and grading of the available 
quality of evidence was performed by the paediatric subgroup of the ESCMID-ECMM-
European Respiratory Society (ERS) Aspergillus disease guideline working group, which 
was assigned the mandate for the development of neonatal and paediatric specific 
recommendations.  
Questions: Questions addressed by the guideline included the epidemiology of IA in 
neonates and children; which paediatric patients may benefit from antifungal prophylaxis; 
how to diagnose IA in neonates and children; which antifungal agents are available for use 
in neonates and children; which antifungal agents are suitable for prophylaxis and 
treatment of IA in neonates and children; what is the role of therapeutic drug monitoring of 
azole antifungals and which management strategies are suitable to be used in paediatric 
patients. This guideline provides recommendations for the diagnosis, prevention and 
treatment of IA in the paediatric population, including neonates. The aim of this guideline is 
to facilitate optimal management of neonates and children at risk for or diagnosed with IA.  
 
  
INTRODUCTION 
Epidemiology of invasive aspergillosis in neonatal and paediatric patients 
Invasive aspergillosis (IA) is a serious infectious complication observed in neonates and in 
children with primary or acquired immunodeficiencies. Quantitative or qualitative 
deficiencies of neutrophil granulocytes are the major risk factors to develop IA. 
Consequently, paediatric patient groups vulnerable to IA include children with 
haematological malignancies and primary immunodeficiencies, children undergoing 
haematopoietic stem cell or solid organ transplantation, suffering from graft-versus-host 
disease, and children receiving chemotherapy or immune modulating treatment. In 
addition, neonates and children admitted to intensive care units are at an increased risk to 
develop IA [1-6].  
The incidence of IA in the various paediatric patient groups is ill-defined and varies 
depending on the intensity of treatment protocols for malignancies and organ transplants, 
the use of antifungal prophylaxis, the challenges in diagnosing IA and the inconsistencies 
in diagnostic criteria used [7]. As neonates and children at risk for IA are in general also at 
risk for other invasive fungal infections caused by either yeasts or molds, and a proven 
diagnosis of an invasive mold infection is rarely obtained, epidemiological studies have 
focused on the incidence of invasive fungal disease (IFD) using the EORTC consensus 
criteria [8] or a modification of those. A retrospective cohort study using the U.S. 2000 
Kids’ Inpatient Database has provided the most robust estimate of the incidence of 
paediatric IA so far [6]. The incidence rate of IA among immunocompromised children 
(including those with malignancies, non-malignant haematologic or immunologic disorders 
and transplant patients) was 0.4% with incidences ranging from 0.1% to 30% [6]. Highest 
incidences were reported among allogeneic haematopoietic stem cell transplant (HSCT) 
recipients, lung transplant recipients, primary immunodeficiencies and acute myeloid 
leukaemia (AML). Similar incidence rates have been reported among paediatric HSCT 
patients by other studies [9-13]. The overall case-fatality rates of IA in children with cancer 
and those receiving a transplant ranges between 20% and 50%, but is highly determined 
by the extent of invasive disease and the severity of immunosuppression [4,14,15]. 
Incidences of IA range from 26% to 45% in children with chronic granulomatous disease 
(CGD) and IA is the single most common infectious cause of death [16]. Neonatal IA is an 
occasional finding with a favourable outcome in 73% of patients [17].  
Similar to adults, most children with IA present with pulmonary disease with dissemination 
to the central nervous system in up to 15% [18]. Exceptions are neonates, who are 
suffering more often from invasive cutaneous aspergillosis [17,19].  Aspergillus fumigatus 
and A. flavus are the most common species causing IA in neonates and children [14,15]. 
Invasive aspergillosis in children with CGD is predominantly caused by A. fumigatus and 
A. nidulans, with the latter species only sporadic encountered in other patient groups 
[16,20-22].  
Motivation for guideline development 
International professional organisations have noticed that the development of paediatric 
specific guidelines for the management of invasive fungal diseases has been an unmet 
need and have therefore initiated an effort to develop such guidelines. The European 
Society for Clinical Microbiology and Infectious Diseases (ESCMID) – Fungal Infections 
Study Group (EFISG) was the first to develop a specific guideline for the management of 
invasive candidiasis in neonates and children [23]. Next to this fungal disease-specific 
guideline, a guideline for the management of invasive fungal infections in paediatric 
patients with leukaemia and haematopoietic stem cell transplantation has been elaborated 
[24]. This guideline has been developed within the European Conference on Infections in 
Leukaemia (ECIL) addressing a specific patient population at risk for developing invasive 
fungal disease. In the document presented here, the ESCMID-ECMM (European 
Confederation of Medical Mycology) guideline for the management of invasive 
aspergillosis in neonates and children is presented, the third paediatric specific guideline 
for management of invasive fungal diseases. It is related to the 2017 ESCMID-ECMM-
ERS (European Respiratory Society) guideline covering the diagnosis and management of 
aspergillosis in all patient populations at high risk to develop either invasive or chronic 
aspergillosis whose executive summary has recently been published [25].  
Aim of guideline 
The recommendations presented in this guideline are intended to facilitate optimal 
management of neonates and children, aged 0 to 18 years of age, at risk for invasive 
aspergillosis and those diagnosed with invasive aspergillosis. They are not necessarily 
exhaustive. Contraindications, drug–drug interactions and specific warnings for each 
antifungal compound have to be considered by the physician responsible for an individual 
patient’s care.  
This paediatric specific guideline extends the summarized guidance about the prophylaxis 
and treatment of IA in children as found in the executive summary [25]. In the present 
guideline, paediatric specific guidance with respect to diagnostic modalities, secondary 
prophylaxis, management strategies, breakthrough infection and salvage treatment, as 
well as specific recommendations for therapeutic drug monitoring of azole antifungals can 
be found. An extensive overview of the available literature supporting the 
recommendations is also presented.  
For specific recommendations regarding preparation of diagnostic samples, microscopic 
examinations, cultures, species identification, susceptibility testing, and recommendations 
for infection prevention in the hospital environment, the reader is referred to the executive 
summary [25].  
Guideline development  
The paediatric subgroup (AW, TL, ER, EC, RB, AG) of the ESCMID-ECMM-ERS 
Aspergillus disease guideline working group was assigned the mandate for the 
development of neonatal and paediatric specific recommendations as summarized in the 
executive summary [25]. During 2012-2014, documents and discussions were shared by 
e-mail, teleconferences, and face-to-face meetings. Once a first consensus was reached 
among the paediatric group, the preliminary recommendations were presented to the 
whole group, discussed, developed further, finalized by group consensus, and presented 
in part at ECCMID 2014. This summary was reviewed and approved by all authors and 
sent to the ESCMID guideline director for public review. An executive summary was 
prepared and submitted to Clinical Microbiology and Infection in 2017 and published in 
2018 after peer review [25]. The methods to evaluate the quality of evidence and to reach 
group consensus recommendations have been previously described [26]. A modified 
USPSFTF grading system [www.uspreventiveservicetaskforce.org/] was adopted for 
assessing quality of evidence and assigning strength of recommendation. Definitions of 
the strength of recommendation and quality of the published evidence are provided in 
Table 1. The quality of the evidence was indexed with a ‘t’ (transferred evidence) if the 
evidence resulted from studies in different patient populations, e.g. adult patients.  
As the period between the development of the guideline and the publication of the 
executive summary was prolonged, the paediatric group conducted a review of the 
literature published between 2014 until the end of 2017, and discussed the findings in a 
face-to-face meeting at the beginning of 2018. Relevant new literature was included in the 
text of the guideline, but no changes were made in the consented recommendations as 
published in the executive summary [25]. All authors fulfill the criteria set forth by the 
International Committee of Medical Journal Editors (ICMJE). For the purpose of this 
guideline, further requirements reflecting sufficient author contribution were 
responsiveness throughout the guideline process and disclosure of conflicts of interests.  
In the process of defining therapeutic recommendations for neonates and children we 
have taken into account the paediatric development regulations and guidelines from the 
European Medicines Agency (EMA) [27,28]. The EMA accepts the requirement for 
extrapolation of evidence for efficacy from studies in adults to paediatric patients, or from 
older to younger paediatric patients when the following criteria are met: (i) underlying 
condition and cause of targeted disease and expected response to therapy are similar; (ii) 
data from clinical studies on pharmacokinetics, safety and tolerance are available for 
paediatric patients; and (iii) supportive paediatric efficacy data exists. 
 
 
1WHICH PAEDIATRIC PATIENTS MAY BENEFIT FROM ANTIFUNGAL PROPHYLAXIS? 
Primary antifungal chemoprophylaxis may be indicated in patients who are at high risk for 
developing invasive aspergillosis (IA).  Although not defined in a rigorous scientific 
manner, an incidence rate of the disease in a given population of 10% and higher is 
usually considered as high risk. Following this definition, paediatric populations at high risk 
to develop IA include children with de novo or recurrent acute leukemia (e.g. AML, 
recurrent AML and ALL; de novo ALL depending on treatment protocol and additional risk 
factors including prolonged and profound granulocytopaenia and treatment with 
glucocorticosteroids);  those with bone marrow failure syndromes (e.g. myelodysplastic 
syndrome (MDS) and very severe aplastic anaemia (VSAA)) with profound 
granulocytopaenia;  allo-HSCT recipients; patients with chronic granulomatous disease 
and those undergoing lung or heart/lung transplantation or high-risk liver transplantation 
[20-22,29-36]. Of note, low or sporadic risk is not equal to no risk and a personalized 
assessment may be warranted for individual patients not belonging to the listed entities 
based on the presence of specific individual risk factors. Most importantly, the local 
epidemiology is an important consideration for designing an appropriate prophylaxis 
strategy in a given institution. As IA in neonates is reported only occasionally, specific 
antifungal prophylaxis against IA in this patient group is not recommended (no grading). 
 
3. WHAT ANTIFUNGAL AGENTS ARE AVAILABLE FOR MANAGEMENT OF INVASIVE 
ASPERGILLOSIS IN NEONATES AND CHILDREN? 
Unfortunately, not all licensed antifungal agents are approved for use in neonates and 
children. In addition, for those antifungals with a paediatric label, it often does not cover all 
paediatric age groups and indications. Paediatric studies to define appropriate doses in 
specific age groups and in children with specific underlying diseases are still scarce. Table 
2 provides an overview of antifungal agents, which can be used in neonates and children 
for the prophylaxis and treatment of IA, the recommended dosages, and the status of 
regulatory approval. 
 
 
4. WHAT ANTIFUNGAL AGENTS ARE RECOMMENDED FOR THE PROPHYLAXIS OF 
INVASIVE ASPERGILLOSIS IN CHILDREN? 
Considering the patient populations at high risk for IA, the following recommendations are 
made with specific comments, systematic references and dosages provided in tables 2, 3, 
and 4. 
Children undergoing allogeneic HSCT  
Antifungal prophylaxis against IA and other relevant IFDs (i.e., invasive candidiasis) should 
be considered during the granulocytopaenic phase until engraftment (B-IIt). Options 
include itraconazole (A-IIt); posaconazole for patients ≥ 13 years of age (A-IIt); and 
voriconazole for patients > 2 years of age (A-IIt).  Secondary alternatives include liposomal 
amphotericin B (B-IIt); micafungin (B-IIt); and, with less strength of evidence, aerosolised 
liposomal amphotericin B (C-IIt) and caspofungin (C-II). In the absence of Graft-versus-
Host Disease (GvHD), antifungal prophylaxis may be continued post engraftment until 
discontinuation of immunosuppression and signs of immune recovery (no grading).  
In the presence of GvHD requiring augmented immunosuppression (including but not 
limited to the use of glucocorticosteroids in therapeutic dosages (≥ 0.3 mg/kg/day 
prednisone equivalent) or use of anti-inflammatory antibodies), prophylaxis against IA and 
other relevant IFDs is recommended (A-IIt). Options include posaconazole for patients ≥ 
13 years of age (A-IIt); and voriconazole for patients > 2 years of age (A-IIt). Secondary 
alternatives are itraconazole (B-IIt); liposomal amphotericin B (B-III); micafungin (B-III); 
and, with less strength of evidence, aerosolised liposomal amphotericin B (C-III) and 
caspofungin (C-III). If itraconazole, posaconazole, and voriconazole are selected, 
therapeutic drug monitoring (TDM) is recommended with target concentrations similar to 
those recommended for adults. Special caution must be exerted with the concomitant use 
of itraconazole, posaconazole and voriconazole with immunosuppressants such as 
cyclosporine, tacrolimus, and sirolimus [120,121]. 
Children with de novo or recurrent acute leukaemia   
Antifungal prophylaxis is recommended for patients with AML, recurrent AML and 
recurrent ALL (A-IIt); the recommendation for prophylaxis in de novo ALL depends on the 
treatment protocol and additional risk factors including prolonged and profound (≥ 10 days 
with an absolute neutrophil count <500/uL) granulocytopaenia and treatment with 
glucocorticosteroids. Options include itraconazole (A-IIt); posaconazole for patients ≥13 
years of age (A-IIt); and voriconazole for patients > 2 years of age (A-IIt).  Secondary 
alternatives include liposomal amphotericin B (B-IIt); micafungin (B-IIt); and, with less 
strength of evidence, aerosolised liposomal amphotericin B (C-IIt) and caspofungin (C-II). 
If itraconazole, posaconazole, and voriconazole are selected, therapeutic drug monitoring 
(TDM) is recommended with target concentrations similar to those recommended for 
adults. Special caution must be exerted with the concomitant use of itraconazole, 
posaconazole and voriconazole with vincristine and other anticancer agents [122-124]. 
Children with bone marrow failure syndromes 
Antifungal prophylaxis is recommended for patients with profound and prolonged 
granulocytopaenia (A-IIt). In the absence of separate data, recommendations are similar to 
those made for patients with acute leukemia. 
Children undergoing lung and/or heart transplant 
Prevention of IA in children with solid organ transplantation depends on the type of 
transplant. In children undergoing lung (+/-heart) transplantation, anti-Aspergillus 
prophylaxis is strongly recommended for ≥ 12 months (A-IIIt). In heart transplantation 
alone the risk for IA is low and there is no need of prophylaxis (D-IIIt). However, heart 
transplantation with high-risk profile (e.g. acute rejection, re-exploration, haemodialysis) is 
an indication for antifungal prophylaxis (B-IIIt).  
Nebulized lipid formulations of amphotericin B or systemic azoles with anti-mold activity 
may be used for IA prevention [125] (no grading). The effectiveness and safety of 
voriconazole prophylaxis has been studied in lung transplant patients [126]; the overall 
incidence of IA was 1.5% in the universal prophylaxis voriconazole group, compared with 
23.5% in the guided prophylaxis group.  
Children undergoing liver transplant 
Antifungal prophylaxis is only recommended in those children exhibiting a high-risk profile 
(e.g. model for end-stage liver disease [MELD] score >30, liver failure, renal failure, re-
intervention) (B-IIIt). Duration of prophylaxis is unclear but a 3 to 4-wk treatment or 
treatment until resolution of risk factors seems appropriate [45]. The drug of choice 
remains controversial (no grading). Lipid amphotericin B has shown a significant reduction 
of IFI without a mortality reduction [127] but is limited by its potential for nephrotoxicity. 
Echinocandins are not nephrotoxic and promising results have been published in 
preventive studies focusing on high-risk liver transplant recipients [51,128].  
Children undergoing kidney transplant 
In paediatric kidney transplant recipients, antifungal prophylaxis to prevent IA is not 
recommended (D-IIIt).  
Children with chronic granulomatous disease 
Prevention of IA plays a central role in the clinical management of children with chronic 
granulomatous disease (CGD) and consists of reducing environmental exposure to molds 
and the prophylactic use of antifungals. Itraconazole prophylaxis has shown to significantly 
reduce invasive fungal disease in CGD patients [54] and is recommended as prophylaxis 
(A-II). Posaconazole is a favourable alternative (A-III). The use of prophylactic 
recombinant human interferon-γ has shown to decrease the risk of severe infections 
(including fungal infections) in CGD by 70% [130], but controversy remains about its use in 
routine prophylaxis [131-133]. 
Secondary prophylaxis 
Available data suggest a natural relapse rate of 30 to 50% in hematological patients with 
proven or probable IFDs during subsequent courses of chemotherapy or allogeneic HSCT 
[134]. Cohort studies in adults indicate that voriconazole, itraconazole, caspofungin, and 
liposomal amphotericin B may all be effective in reducing relapse rates in patients who had 
responded to initial antifungal therapy; data for paediatric patients are limited [24]. On the 
basis of these data, secondary prophylaxis to prevent recurrence or a second episode of 
invasive aspergillosis is recommended for granulocytopaenic or immunocompromised 
patients as long as these risk factors are persisting (A-IIt). Prophylaxis should be 
implemented with an antifungal agent that is targeted against the Aspergillus species that 
caused the first episode and the site of infection [135-139]. No general recommendations 
can be made about the minimum duration of therapy and the extent of response prior to 
continuing anticancer treatment or starting the conditioning regimen. 
 
5. HOW TO DIAGNOSE INVASIVE ASPERGILLOSIS IN NEONATES AND CHILDREN? 
Early diagnosis of IA is particular challenging in children due to difficulties in obtaining 
enough sample volumes, the need for anaesthesia to perform certain diagnostic 
procedures, and limited clinical data with respect to the usefulness of fungal biomarkers 
and molecular detection methods. Standard diagnostic procedures for IA are not different 
between paediatric and adult patients. Both microscopy and culture should be attempted 
on appropriate specimens from patients at high-risk for IA. The following recommendations 
are made with specific comments and systematic references in table 5. 
Imaging studies 
Imaging studies, in particular computed tomography (CT) scan of the chest should be used 
in high risk patients as early diagnostic modality to detect IA in an early phase triggered by 
persistent febrile neutropenia, clinical findings, positive serum galactomannan (GM) or 
Aspergillus positive sputum (A-IIt). Importantly, radiographic findings considered typical of 
pulmonary IA in adults, such as the halo sign, the air crescent sign, and cavities, are not 
seen in the majority of children with pulmonary IA, whereas in immunocompromised 
children with IPA, unspecific findings are detected more often. In neutropenic children, CT 
scans of the chest have a higher sensitivity in the early detection of IPA than conventional 
X-ray (C-II for the latter), whereas in non-neutropenic immunocompromised children 
following solid organ transplantation or those with CGD pulmonary infiltrates are in most 
cases visible on X-ray as well (A-III). However, for evaluation of extensiveness of disease, 
CT scan of the chest is recommended in this patient population (A-III). Whether pulmonary 
CT angiography will improve specificity in the diagnosis of IPA in children needs further 
evaluation [182]. In addition to chest imaging, evaluation of other sites such as the 
paranasal sinuses, the central nervous system (CNS) or the abdomen may be necessary. 
Similar to adults, invasive diagnostics such as broncho-alveolar lavage (BAL) or CT-
guided biopsies should be strongly considered for the diagnosis of IA [183-186].    
Non-culture based assays 
In paediatric patients, the GM assay in serum seems to have a sensitivity and specificity 
profile that is similar to that in adults [153]. However, careful interpretation is necessary 
due to limitations such as variations regarding the cut-off or the definition of test positivity. 
GM testing can be used both as a screening tool in paediatric patients considered at high-
risk for developing IA (B-II) as well as a diagnostic tool in paediatric patients suspected of 
having  developed IA, e.g., those with clinical symptoms or imaging abnormalities (B-II). 
GM screening should not be performed in neonates and children at low risk for IA (D-III). 
Bifidobacteria comprising over 75% of the total fecal microflora of neonates and young 
infants, have been shown to explain the high false positive GM test results, and is 
therefore of less value in this young patient population [187]. Systemic mold-active 
prophylaxis may decrease the performance of the test, and the assay is not validated in 
non-neutropenic patients. In view of adult data, the limited studies in the paediatric 
population also suggest the usefulness of GM testing in BAL (B-IIt). Although not validated 
for detection in cerebrospinal fluid (CSF), a highly elevated GM in the CSF is indicative of 
CNS aspergillosis in the appropriate setting (B-II).  
In addition to Aspergillus infections, ß-D-glucan (BG) may detect infections due to fungi 
such as Candida spp., Pneumocystis jirovecii, or Fusarium spp. Data on BG testing in 
serum or plasma are extremely limited in the paediatric population. In addition, the optimal 
cut-off in neonates and children is unknown, as mean BG levels are higher in 
immunocompetent children than in adults [162,180,187,188]. Therefore, at present, there 
is a recommendation against the use of BD for screening or for the evaluation of 
suspected IA in immunocompromised children at high-risk to develop IA (D-III).   
PCR-based assays are increasingly evaluated for the early detection of IA. Whereas two 
paediatric studies reported on a high negative predictive value of Aspergillus specific PCR 
used for screening in hematology patients at high risk for IA [162,189], 6 other studies 
showed a wide range of sensitivities and specificities when using a PCR assay (4 
Aspergillus specific, 2 pan-fungal) as a diagnostic tool in immunocompromised children 
suspected of having IPA [190-195]. None of those studies included neonates. Due to the 
lack of paediatric data no recommendation can be made for its use in diagnosing IA in 
neonates and children. 
 
6. WHAT ANTIFUNGAL AGENTS ARE RECOMMENDED FOR THE TREATMENT OF 
INVASIVE ASPERGILLOSIS IN NEONATES AND CHILDREN? 
General management principles of IA are in line with those in adults and include prompt 
initiation of antifungal therapy, control of predisposing conditions (e.g., colony-stimulating 
factors for granulocytopaenic patients), reduction of immunosuppressive therapy, and 
surgical interventions in individual patients [24,24]. Duration of treatment is not defined, 
and decisions when to stop antifungal therapy should take into account clinical response, 
the degree of immunosuppression and/or recovery from neutropenia, engraftment post-
HSCT and recovery of GvHD.  
Children with HSCT, leukemia, other cancers, and bone marrow failure syndromes  
Recommendations for primary treatment of proven or probable IA (see table 6) include 
intravenous voriconazole with TDM (A-IIt; limited to children ≥ 2 years) and liposomal 
amphotericin B (B-IIt); the weaker recommendation for liposomal amphotericin B is due to 
the fact that the pivotal phase III trial was not a head-to-head comparison to voriconazole 
as the reference agent but a comparison between two different dosage strategies. 
Secondary options include caspofungin (C-IIt); the combination of liposomal amphotericin 
B with an echinocandin (C-IIt); the combination of voriconazole with an echinocandin (C-IIt 
a); amphotericin B lipid complex (C-III); and intravenous itraconazole with TDM (C-III). The 
use of amphotericin B deoxycholate and of amphotericin B colloidal dispersion is 
discouraged due to poor tolerability (D-IIt). 
Children undergoing solid organ transplantation 
There are no studies of primary treatment in paediatric SOT patients with IA. The 
recommendations are derived from children and/or adults with haematological 
malignancies and IA (see table 6). Decreasing the degree of immunosuppression if 
possible but without jeopardizing graft viability is of importance to control IA. Primary 
treatment of proven or probable IA in children having received any solid organ transplant 
includes voriconazole (A-IIt) and liposomal amphotericin B (B-IIt) [199-201]. Secondary 
options [213-215,226] are similar to those recommended for paediatric haemato-oncology 
populations and are summarized in table 6.  
Children with chronic granulomatous disease  
The recommendations for primary therapy in CGD patients with IA are derived from those 
for children with haematological malignancies as no studies have been performed in CGD 
patients (see table 6). In addition, the unique epidemiology of IA in CGD patients has been 
taken into account which is characterized by the occurrence of A. nidulans, often resistant 
to amphotericin B [20-22,245]. To make a causative diagnosis is of utmost importance in 
this particular patient group as unusual Aspergillus species with different susceptibility 
profiles are more frequent compared to other patient groups [246,247]. In general it is 
more feasible to perform invasive diagnostics compared to children with underlying 
haematological malignancies. Posaconazole has been shown to be safe and effective in 
CGD patients with refractory IA, has good activity against A. fumigatus and A. nidulans, 
and is a reasonable alternative (no grading). 
Neonates 
Invasive aspergillosis in neonates is more often cutaneous [17,19]. Liposomal 
amphotericin B is the drug of choice (A-III), as voriconazole is not approved for children < 
2 years of age and dosages to be administered are unclear. Limited safety data for the use 
of liposomal amphotericin B in neonates is available [248-251], but PK studies are lacking. 
Amphotericin B deoxycholate (C-III) is an alternative as minimal toxicity is observed in 
neonates and is relatively safe and efficacious [237-239,252]. Other alternative agents are 
amphotericin lipid complex (C-III) [233], mold-active azoles (C-III) [238] and echinocandins 
(C-III) [255-260]. 
 7. WHAT IS THE ROLE OF THERAPEUTIC DRUG MONITORING IN NEONATES AND 
CHILDREN? 
Over the past two decades there has been a surge in information supporting the use of 
therapeutic drug monitoring (TDM) of azole antifungal agents [261,262]. Paediatric 
patients display differences in the clearance of antifungal azoles and display a high inter-
individual variability in exposure [263], Augmented, TDM-guided exposure may be 
required in the setting of infection at sanctuary sites and for infections with strains with 
higher MICs. Other situations where TDM may be indicated is the setting of intravenous to 
oral step down therapy or in the setting of drug-drug interactions. It should be noted that 
target trough concentrations have been defined mostly for adult populations and have not 
been fully validated in paediatric patients. In the setting of azole resistance, current 
recommended target concentrations are not valid and alternative treatments should be 
used [264-266].  
As most azole antifungals are given with a loading dose and steady state conditions are 
reached at an early time point, it is feasible to have a first assessment on day 3 of therapy. 
The frequency of resampling is driven by the degree of intra-individual variability 
[http://www.eci.-leukaemia.com/telechargements2015/ECIL6-triazole-TDM-07-12-2015-
Lewis-R-et-al.pdf]. For compounds with a high degree of variability (i.e., voriconazole or 
itraconazole) sampling 1-2 times per week for the first four weeks of treatment is 
recommended with a reduction in frequency thereafter. For drugs with limited intra-
individual variability, monitoring once weekly at the start of therapy is recommended. This 
may be reduced after adequate exposure has been confirmed to once every two weeks 
[http://www.ecil-leukaemia.com/telechargements2015/ECIL6-Triazole-TDM-07-12-2015-
Lewis-R-et-al.pdf]. Patients on chronic/prophylactic therapy (such as CGD patients) 
typically are monitored on every outpatient visit (no grading due to the lack of data). 
Itraconazole 
For oral administration, the oral solution should be preferred over the tablet form due to 
better absorption of the parent. The pharmacokinetics of itraconazole have been well 
described for paediatric patients [58,60,63]. TDM is strongly recommended [57,231,267]. 
For prophylaxis, trough levels of 0.5-4 mg/L (itraconazole +hydroxy-itraconazole) should 
be achieved; for treatment, trough concentrations of 1-4 mg/L are recommended (AII 
(efficacy), B11 (safety)) [25,57,267-270]. Concentrations should be assessed after 5 days 
(3 days if loading dose is administered), and repeated during prophylaxis and therapy. 
Posaconazole  
Posaconazole is available as an oral suspension, as gastroresistant tablet and an IV 
formulation. Dosing in paediatric patients has not formally been established [271], and 
dosing recommendations in adults vary according to the formulation. For oral 
administration, the tablet formulation is preferred due to more consistent absorption. In the 
absence of established dosing regimens for children, TDM is recommended when 
administering posaconazole for prophylaxis [65,69,272], and targeted therapy [273]. For 
prophylaxis, trough concentrations of > 0.7 mg/l (BII, efficacy), and for treatment trough 
concentrations >1 mg/l (AII, efficacy) are recommended [25]. Concentrations should be 
assessed on day 3 of administration, and repeated during prophylaxis and therapy. 
Voriconazole  
Voriconazole is available as a solid oral tablet, an oral solution and an IV formulation. The 
drug shows a high degree of both inter- and intra-individual variability in pharmacokinetics 
[85,274-277] is both a substrate as well as inhibitor of CYP 450 mediated drug metabolism 
and carries a high potential for drug-drug interactions. TDM is recommended, and plasma 
trough concentrations of 1-5.5 mg/L are considered adequate for prophylaxis and 
treatment of IA (AII, safety and efficacy) [25]. A slightly higher trough level (2-6 mg/L) is 
recommended for disseminated and/or CNS infections, or infections caused by Aspergillus 
species with an elevated MIC of 2 mg/L (AII, safety and efficacy [25,77,78,278-280]. 
Concentrations should be assessed on day 3 of therapy, and repeated in regular intervals 
during therapy regardless of previous concentrations. 
 
8. HOW TO MANAGE BREAKTHROUGH INVASIVE ASPERGILLOSIS? 
For children receiving mold-active azole prophylaxis, it is recommended to choose a non-
azole antifungal for empiric or pre-emptive therapy. Liposomal amphotericin B (A-IIt) is 
recommended as first line antifungal therapy in those cases [281-285]. Caspofungin is 
recommended as an alternative (C-II) based on a salvage therapy study conducted in 
patients who had breakthrough infections while on amphotericin B [286].  
 
9. WHAT ARE THE APPROACHES TO SALVAGE THERAPY? 
Salvage- or second-line treatment refers to antifungal treatment in patients failing to 
respond or being intolerant to the initial treatment. Identification to species level and the 
resistance profile of the causative Aspergillus sp., is of utmost importance. Although not 
formally investigated, a switch in class should be considered when antifungal therapy is 
changed for refractory disease. In the absence of separate data for non-hematological 
patients, recommendations made here apply to all hematological and non-hematological 
patient populations (see table 7). Options for salvage treatment include voriconazole plus 
TDM in voriconazole-naïve patients (A-IIt; limited to children ≥ 2 years) and liposomal 
amphotericin B in amphotericin B-naïve patients (B-IIt), respectively. Further options 
approved in paediatric patients include amphotericin B lipid complex (B-II) and 
caspofungin (B-IIt), and, for patients ≥13 years of age, posaconazole plus TDM (B-IIt). Few 
and uncontrolled data exist on combination therapy with either voriconazole or an 
amphotericin B product plus an echinocandin for salvage treatment (C-IIt), for micafungin 
(C-IIt), and for itraconazole (C-III) and no strong recommendations can therefore be made. 
Similar to primary therapy, the use of amphotericin B deoxycholate and of amphotericin B 
colloidal dispersion is discouraged due to poor tolerability (D-IIt). 
 
10. WHICH MANAGEMENT STRATEGIES ARE AVAILABLE IN CHILDREN WITH A 
CLINICAL SUSPICION OF INVASIVE ASPERGILLOSIS? 
The administration of empirical antifungal therapy is a common practice that consists of 
administering a systemic antifungal drug in a persistently febrile, neutropaenic cancer 
patient after a variable period of empirical antibacterial therapy (usually 4 to 7 days) in the 
absence of any further clinical, radiologic or microbiologic documentation of a fungal 
infection [292]. Empiric treatment is defined as a fever-driven treatment approach and 
aimed to treat IA as early as possible in patients at high-risk for IA before further clinical 
signs and symptoms develop. Four prospective randomized clinical trials have been 
performed in paediatric haemato-oncological populations [244,293-295].  
The empirical approach has the potential to result in an overuse of antifungals as most 
patients receiving empirical antifungal therapy ultimately do not have an invasive fungal 
infection. A pre-emptive or a diagnostic-driven approach has been advocated and has 
shown to be a safe alternative if diagnostic modalities are accessible in a timely way. In 
this approach, new abnormalities on a chest-CT and/or a positive serum galactomannan 
are used to define the start of antifungal therapy. A number of studies in adult high-risk 
populations have demonstrated the feasibility and safety of this approach and a reduction 
in the use of antifungal agents without increased mortality [296-299]. An observational 
study of a diagnostic treatment approach in a paediatric haemato-oncological population 
spanning several decades showed an increased survival from invasive fungal disease, a 
higher number of diagnosed infections and less antifungal consumption compared to 
historical controls with different management strategies [300]. Recently, the results from 
the first randomized clinical trial, comparing the efficacy of pre-emptive versus empirical 
antifungal therapy in children with high risk febrile neutropenia, were published [301]. The 
results showed that a pre-emptive approach was as effective as the empirical approach 
with a significant reduction of antifungal use in the pre-emptive group. Therefore, a 
diagnostic driven treatment strategy can be recommended in children (A-II) (see table 8), if 
the diagnostic infrastructure allows timely access to CT imaging, galactomannan testing 
and the ability to undertake bronchoscopies with bronchoalveolar lavage and appropriate 
microbiological work-up. 
 
11. WHAT ANTIFUNGAL AGENTS ARE RECOMMENDED FOR EMPIRIC AND PRE-
EMPTIVE TREATMENT IN NEONATES AND CHILDREN? 
Summarizing the results of the 4 prospective randomized clinical trials in paediatric 
haemato-oncological patients [244, 293-295], similar efficacy was observed for 
caspofungin and liposomal amphotericin B, with liposomal amphotericin B being more 
efficacious than amphotericin B deoxycholate and amphotericin B colloidal dispersion. 
Caspofungin was better tolerated than liposomal amphotericin B, with the latter showing 
less toxicity compared to the other amphotericin B formulations. Therefore, caspofungin or 
liposomal amphotericin B are recommended and approved for use in an empiric treatment 
approach (A-I) (see table 8).  
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